Where to buy CJC-1295 / ipamorelin blend.

You can buy the CJC-1295 and ipamorelin blend from research-supply vendors online, and that is the only channel left. The compounding-pharmacy route that once carried this pairing closed across 2023 to 2025. Where to buy CJC-1295 / ipamorelin blend therefore means picking a vendor who can tell you which of the two CJC-1295 molecules is in the vial.

CJC-1295 / Ipamorelin

Referenced in this guide

Batch-matched COAHPLC + mass specResearch use only

The CJC-1295 / Ipamorelin referenced throughout this article, supplied as a research compound with a certificate of analysis matched to the lot you receive — the check this site argues you should hold any supplier to.

Shop CJC-1295 / Ipamorelin

• CoA. Certificate of Analysis. A one-page lab report showing the specific lot’s purity, identity, and water content. For a blend it must cover each component separately.
• ISO/IEC 17025. The international quality standard for testing labs. A 17025-accredited lab has been audited by a third party for technical competence.
• DAC. Drug Affinity Complex. A maleimidopropionic acid linker attached to CJC-1295 that binds serum albumin and extends elimination half-life from minutes to days.
• Modified GRF 1-29. The other name for CJC-1295 without DAC. A 29-residue GHRH analog with a half-life measured in tens of minutes.
• 503A pharmacy. A U.S. compounding pharmacy licensed to make custom prescription medications for individual patients, operating under section 503A of the Federal Food, Drug, and Cosmetic Act.
• Co-lyophilized. Both peptides freeze-dried together into a single cake in one vial, rather than filled separately and combined later.

Where can you buy the CJC-1295 / ipamorelin blend?

The CJC-1295 and ipamorelin blend comes from research-supply vendors online. That's effectively the whole answer in 2026. A 503A compounding pharmacy used to be a real route, and the FDA closed it. The gray channel exists and we'd avoid it.

• Research-supply vendors: The working channel. Co-lyophilized vial labeled for laboratory research use only, $80–$150 per 5/5 vial, no prescription.
• 503A compounding pharmacies: Closed. Both components landed on the FDA's bulks-not-eligible lists, and the channel shut across 2023–2025.
• Gray-channel sellers: Social marketplaces, forum sellers, drop-shipped storefronts with no named testing lab. For a two-component vial, the exposure doubles.

Detail on all three, including what the pharmacy closure did to the research market, is in the channels section below.

Six vendors, all checked on 13 August 2026 against what each will show you before you pay: a third-party certificate you can open, and whether the testing lab is named in the vendor's own copy or only inside the PDF. We did not verify the blend prices, so there is no price column here — pricing across these same vendors is benchmarked on BPC-157 in our full vendor comparison, where the spread runs $6.30–$12.45 per mg. Stock varies by compound, so check each catalogue for the blend.

Three caveats travel with that table. Peptriva and Red Rock sell 10 mg vials only, so their per-milligram figures in the BPC-157 benchmark are not comparable with a 5 mg row. Swiss Chems sells its BPC-157 as the arginine salt rather than the plain peptide, so it is not a like-for-like product. And Red Rock publishes no certificate of analysis at all, despite advertising verified COAs. Where To Buy Peptides earns a commission on purchases made through its links, Peptriva included — see our disclosure.

The identity check specific to this blend: two CAS numbers on one report, 863288-34-0 for CJC-1295 no-DAC and 170851-70-4 for ipamorelin — plus a vendor who will say which CJC-1295 variant the vial is built on, DAC at a 6–8 day half-life or no-DAC at roughly 30 minutes.

What is the CJC-1295 / ipamorelin blend, exactly?

The blend vial holds two unrelated molecules that converge on the same cell. CJC-1295 is a 29-amino-acid synthetic analog of growth hormone-releasing hormone, carrying substitutions that resist enzymatic breakdown.

Ipamorelin is a 5-amino-acid peptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, developed at Novo Nordisk in the late 1990s as a selective growth hormone secretagogue.

They aren't variations on a theme. CJC-1295 binds the GHRH receptor on pituitary somatotrophs and doesn't bind the ghrelin receptor at all.

Ipamorelin binds GHS-R1a, the receptor your own ghrelin uses, and doesn't touch the GHRH receptor. See Memdouh and Lu.

That receptor separation is the entire reason the pairing exists. Both receptors sit on the same pituitary cell and route through different intracellular cascades. Activating both at once produces a larger growth hormone pulse than the arithmetic sum of either alone.

A 2026 review by Rahman and colleagues groups CJC-1295 and ipamorelin with sermorelin, tesamorelin and AOD-9604 as GH secretagogues acting through the GH/IGF-1 axis.

The pairing is mechanistically coherent. It is not clinically validated, a distinction we cover in the stack research review.

Legitimate blend material is a white lyophilized cake in a sealed glass vial, labeled with both component masses, the batch identifier, and a lot-matched CoA. The vial should state the CJC-1295 variant in words, not leave it to inference.

Which CJC-1295 is in the blend, DAC or no-DAC?

Blends are built on CJC-1295 no-DAC, and the vendor has to say so on paper. The DAC question is the single largest sourcing hazard for this blend, and it's a labeling problem rather than a chemistry problem.

CJC-1295 is sold in two forms. The no-DAC form, also marketed as Modified GRF 1-29, is the 29-residue GHRH analog with CAS 863288-34-0 and molecular weight 3367.9 g/mol.

The DAC form carries an extra lysine bearing a maleimidopropionic acid linker. That linker attaches the peptide to serum albumin and stretches elimination half-life from minutes to days, per Memdouh and colleagues. It carries its own CAS registration and adds roughly 280 daltons.

Two molecules. One product name. Vendors routinely fail to specify which one is in the vial, and some list both variants under a single SKU with no analytical distinction on the paperwork.

For a blend, the ambiguity compounds. Blends are built on the no-DAC form because its half-life, on the order of tens of minutes, overlaps the window during which ipamorelin is active.

The DAC variant's multi-day half-life mismatches a short-acting ghrelin mimetic, which makes it a poor stacking partner for pulsatile study designs. A vial silently containing DAC material isn't the compound the co-formulation rationale describes.

The good news is that mass spectrometry settles it instantly. The two forms differ by hundreds of daltons, far outside any instrument's tolerance. A CoA reporting a mass consistent with 3367.9 g/mol is reporting no-DAC material, full stop.

Peptides this size usually appear as multi-charge ions, so expect [M+2H]²⁺ near 1684.9 or [M+3H]³⁺ near 1123.6 rather than a single [M+H]⁺ peak.

How do the three channels compare?

The CJC-1295 and ipamorelin blend reaches buyers through three channels, and their relative importance shifted materially after 2023. Research supply took over what the pharmacies used to carry.

1. Research-supply vendors (now effectively the only channel)

Research supply is where nearly all US buyers now get the blend. The vendor sells a co-lyophilized vial labeled "for laboratory research use only". That sale is legal under US law. Sale for human consumption is not, and the vendor is not a pharmacy.

Here is the documentation we'd verify. A third-party CoA from an ISO 17025-accredited lab named on the report. Separate identity and purity lines for each peptide. Endotoxin testing by LAL, and residual-solvent or counterion content.

The eight general criteria for any peptide vendor apply in full, plus the blend-specific checks below.

2. 503A compounding pharmacies (a channel that closed)

Here is the part most product pages omit. Through the late 2010s and early 2020s, CJC-1295 with ipamorelin was one of the most frequently compounded peptide combinations in US longevity-medicine practice. It was a genuine prescription product, dispensed by licensed 503A pharmacies.

That ended. The FDA's review of nominated bulk drug substances put both CJC-1295 and ipamorelin in the not-eligible category, and across 2023–2025 the compounding channel closed. A 2026 Sports Medicine review classifies both molecules among unapproved peptide therapies where human safety data is scarce.

Two consequences follow for you. First, any clinic still advertizing compounded CJC and ipamorelin is operating outside the substance-eligibility framework, and its material carries no regulatory assurance above research-supply material.

Second, a large volume of demand migrated from pharmacies to research vendors between 2023 and 2025. That is precisely why blend SKUs multiplied, and why documentation quality across them varies so widely.

3. Unverified gray-channel sellers

The gray channel is social-marketplace listings, forum sellers and drop-shipped storefronts with no named testing lab. A 2026 critical review by Coutinho and colleagues identifies the unregulated supply chain as what turns a plausible compound into a documented hazard.

For a two-component vial, your exposure doubles. Either peptide can be underweight, substituted or absent, and no visual inspection of a single white cake will reveal it.

What should you check before buying the blend?

Check the CJC-1295 and ipamorelin blend for four things. Two CAS numbers and two masses on one report. Purity stated per component. A quantitative ratio assay. And an in-use window governed by the shorter-lived component. Each matters more here than for any single peptide.

1. Two CAS numbers, two masses, one report

A blend CoA carries two identity lines, not one. CJC-1295 no-DAC: CAS 863288-34-0, MW 3367.9 g/mol. Ipamorelin: CAS 170851-70-4, MW 711.9 g/mol, formula C₃₈H₄₉N₉O₅, with the observed [M+H]⁺ ion near 712.4.

If only one CAS number appears, the report describes one peptide. You don't know what the second component is, or whether there is one. A report listing both CAS numbers but only one mass-spec result has the same problem in subtler form.

2. Purity per component, never combined

HPLC purity is an area-percent figure: the target peak as a fraction of total peak area. On a two-peptide chromatogram that calculation is ambiguous unless the lab says which peak it applies to.

A blend CoA reading "Purity: ≥99%" with no component breakdown is either sloppy reporting, or a single-peptide report reused for a blend SKU.

A correct report shows two purity figures, one per component, each with its own chromatogram or at minimum its own retention-time annotation. Anything less leaves one clean peptide carrying the number for both.

3. Ratio verification requires quantitative analysis

The ratio assay is the check most buyers skip, and it is the one that establishes you received what you paid for.

Purity tells you each peak is clean. It says nothing about how much of each peptide sits in the vial. A vial holding 8 mg of ipamorelin and 2 mg of CJC-1295 can produce two immaculate ≥99% purity figures and be nothing like a 5/5 blend.

Establishing the ratio needs a quantitative method: quantitative HPLC against a characterized reference standard, or LC-MS with isotope-labeled internal standards. It should be reported as mass per vial, not as a percentage.

One subtlety before you read any ratio claim. A "1:1" blend is a mass ratio, not a molar one.

CJC-1295 is roughly 4.7× heavier than ipamorelin, 3367.9 against 711.9 g/mol. So an equal-mass 5 mg + 5 mg vial holds about 1.5 µmol of CJC-1295 against 7.0 µmol of ipamorelin. Vendors calling the blend "equimolar" are describing a different product from the one they sell.

4. Blend stability and the shorter in-use window

Freeze-dried, both peptides are stable. The co-lyophilized cake holds at −20 °C for roughly 24 months and at 2–8 °C for about 6 months. It survives room-temperature transit for the short durations shipping requires, which is the whole reason the material sells freeze-dried.

Reconstituted, the picture changes, and the CJC-1295 component is why. The no-DAC molecule's solution stability limits the pair, so blend storage guidance sits around 14 days refrigerated rather than the longer windows quoted for ipamorelin alone.

A vendor quoting one generous in-use window, without noting that the shorter-lived component governs it, hasn't thought about the formulation. We'd treat pre-reconstituted blends sold without cold-chain shipping as a documentation gap rather than a convenience.

What does the CJC-1295 / ipamorelin blend cost in 2026?

The blend costs $80–$150 for the standard 5 mg + 5 mg vial. Pricing follows the combined peptide mass, adjusted down slightly for single-vial fill economics.

Ipamorelin is only five residues, but two of them are unnatural amino acids with expensive building blocks: Aib at position 1 and D-2-Nal at position 3. Its per-mg cost sits far above what a pentapeptide would otherwize imply. CJC-1295 at 29 residues is a genuinely long synthesis. Neither is cheap to make honestly.

• 2 mg + 2 mg vial: $40–$75, or $10–$19 per mg combined. Entry size from smaller suppliers.
• 5 mg + 5 mg vial: $80–$150, or $8–$15 per mg combined. The standard retail size and the best per-mg value at most vendors.
• 10 mg + 10 mg vial: $140–$260, or $7–$13 per mg combined. Per-mg value plateaus here.
• Two-vial kit, filled separately: $90–$150 per pair for 5 mg CJC-1295 plus 5 mg ipamorelin. Slightly above the single-vial blend because of the second fill.
• Multi-vial discounts: 10–25% off on 3-packs and 6-packs at most vendors.

Pricing below $80 for a 5/5 vial deserves a direct question about which component was economized. There are two common ways to hit an impossible price.

Short one component, usually the expensive 29-residue one. Or skip the HPLC purification step that separates crude material from ≥98% material. A blend is a convenient place to hide the first, because a single white cake looks identical either way.

Above roughly $20/mg combined, you're paying retail markup rather than synthesis cost. The single-vial format should price at or slightly below the equivalent two-vial kit. A blend priced above the kit charges you a premium for losing the ability to verify each component separately.

Is the CJC-1295 / ipamorelin blend legal to buy?

Yes. The blend is legal to buy as research reference material labeled for laboratory use, and illegal to sell for human consumption. Both components sit in the same regulatory position, which simplifies things:

• United States (FDA): Neither component approved for any indication. Neither is a controlled substance. Legal to buy and sell as research reference material labeled for laboratory use only. Selling for human consumption is illegal; buying as research material is not.
• U.S. compounding (503A): Both placed on FDA’s bulks-not-eligible lists. The compounding channel for this combination effectively closed across 2023–2025.
• European Union (EMA): Neither approved.
• WADA: Both prohibited under category S2 (peptide hormones, growth factors, related substances and mimetics). See the WADA Prohibited List for current categorizations.
• Major sports leagues: Both prohibited.
• Detection: Validated LC-MS/MS methods identify CJC-1295 in urine and blood at sub-ng/mL concentrations (Cristea et al., 2023; Thomas et al., 2024).

The clinical-development history is worth knowing, because vendors sometimes imply otherwize. CJC-1295's therapeutic program was halted years ago and never revived. Ipamorelin reached a Phase III trial for postoperative ileus, missed its primary endpoint, and was discontinued.

Neither molecule reached approval on any indication. We found no randomized controlled trial of the combination for any clinical endpoint.

What are the red flags when buying the blend?

The blend red flag we weigh heaviest is a CJC-1295 with no DAC designation anywhere. Here are eight more we would walk away from.

• “CJC-1295” with no DAC designation anywhere. Not on the vial, not on the CoA, not on the product page. Two different molecules share that name, and the omission means the identity is unverified. This is the number-one blend-specific red flag.
• A single combined purity figure. “≥99% pure” on a two-peptide vial with no per-component breakdown. Area-percent purity across two peaks is not an interpretable number.
• No quantitative assay. Purity without a mass-per-vial assay leaves the ratio entirely unverified. A blend with immaculate purity figures can still be badly out of specification on composition.
• One mass-spec line for a two-component product. Both 3367.9 and 711.9 g/mol should appear, each with its observed ion.
• “Equimolar” or “1:1 molar” marketing on a 5 mg + 5 mg vial. An equal-mass blend is roughly 1:4.7 molar. A vendor describing it as equimolar is either careless with chemistry or copying someone else’s text.
• A generous reconstituted shelf-life claim. The shorter-lived component governs the blend. In-use windows quoted from ipamorelin data alone overstate the pair.
• Clinical or body-composition claims on the product page. “Builds lean mass.” “Reverses aging.” “Improves recovery.” No randomized controlled trial supports any of these for the combination, and a supplier making them has crossed into FDA jurisdiction.
• Compounding-pharmacy framing in 2026. A seller invoking pharmacy legitimacy for this combination is describing a channel that closed. Treat it as a marketing signal, not a quality signal.
• Single-source documentation. Internal QC is not sufficient. Third-party ISO 17025 verification is the standard, and for a blend it must cover both components.

CJC-1295 / Ipamorelin Blend

10 mg (5 mg + 5 mg) ≥99% per component Co-lyophilized

Modified GRF 1-29 (no DAC, CAS 863288-34-0, MW 3367.9 g/mol) co-lyophilized with ipamorelin (CAS 170851-70-4, MW 711.9 g/mol, Aib-His-D-2-Nal-D-Phe-Lys-NH₂). third-party tested reference material; per-component identity by LC-MS and per-component HPLC purity on the COA for every lot, plus endotoxin by LAL.

Learn more

Frequently asked questions

Is the blend legal to buy in the USA?

Yes, as research reference material labeled for laboratory use only. Neither component is FDA-approved as a drug and neither is a controlled substance. Selling the blend for human consumption is illegal. Buying it as research material is not. Both components are WADA-prohibited under S2.

Does “CJC-1295” on a blend label mean DAC or no DAC?

You can't know from the name alone, and that is the entire problem. Blends are conventionally built on the no-DAC form, Modified GRF 1-29 at CAS 863288-34-0, because its half-life overlaps ipamorelin's window. Conventions aren't guarantees.

The DAC form carries a maleimidopropionic acid linker, a separate CAS registration, and a molecular weight roughly 280 Da higher. The mass-spec line on the CoA settles it. Nothing else does.

What should a blend CoA show that a single-peptide CoA doesn’t?

Three things. Two mass-spec identity lines rather than one. Two HPLC purity figures rather than a combined number. And a quantitative assay reporting mass per vial for each component, which is the only test that establishes the ratio. See how to read a Certificate of Analysis for the general framework; the per-component requirement is the blend-specific addition.

Is one vial better than a two-vial kit?

They trade off. A co-lyophilized vial is cheaper and simpler to store. But the cake can't be separated after filling, so you depend entirely on the vendor's quantitative testing for the ratio.

A two-vial kit costs a little more and is easier to characterize component by component. Where component identity must be independently confirmable, we'd call the kit the more defensible format.

Can I still get this from a compounding pharmacy?

Not legitimately. This combination was among the most commonly compounded peptide pairings at U.S. 503A pharmacies through the early 2020s, but FDA’s bulk-substance review placed both components in the not-eligible category, and the channel effectively closed across 2023–2025. Sellers still invoking pharmacy framing in 2026 are describing history, not current regulatory standing.

How does the blend compare to buying each peptide alone?

It depends on the experimental question. A single-agent vial gives a cleaner readout when the question is about one receptor pathway. The blend is the right setup only for questions about GHRH-receptor and ghrelin-receptor co-stimulation.

Our CJC-1295 vs ipamorelin comparison covers the receptor and half-life differences. The single-compound guides for CJC-1295 and ipamorelin cover their verification requirements.

Are there analytical interferences worth knowing about?

One documented oddity. A 2021 method paper by Danila and colleagues reported that cannabidiol and carboxy-THC act as allosteric ligands at GHS-R1a, the receptor ipamorelin targets.

That was developed as a detection approach, not as a characterization of the peptide. It is still a relevant confounder for any receptor-binding assay run in a matrix where cannabinoids may be present.

How much evidence supports the combination specifically?

Less than the marketing implies. The 2020–2026 literature on both molecules is dominated by anti-doping detection methodology, 6 papers, and narrative reviews, another 6. Only 3 primary animal studies exist, all single-agent.

The combination finding most often cited is improved peak muscle force in rodent glucocorticoid-induced wasting. It reaches the literature through a 2026 review rather than a primary paper. Human randomized trials of the combination: zero.